Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Speech, Language, and Hearing Research : JSLHR|April 28, 2001
Mechanisms of discourse comprehension impairment after right hemisphere brain damage: suppression in inferential ambiguity resolutionC A Tompkins, M T Lehman-Blake, A Baumgaertner, et al.
Seminars in Speech and Language|August 28, 1998
Functional outcome assessment of adults with right hemisphere brain damageC A Tompkins, M T Lehman, A D Wyatt, et al.
Proceedings : a Conference of the American Medical Informatics Association. AMIA Fall Symposium|January 1, 1997
Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systemsC R Flowers, A M Garber, M R Bergen, et al.
Epidemiology and Infection|January 24, 2009
Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaksR L Galloway, P N Levett, J W Tumeh, et al.
Expert Review of Anticancer Therapy|January 24, 2017
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrowI B Greenwell, C R Flowers, K A Blum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2017
Unmet needs in the first-line treatment of follicular lymphomaC Casulo, L Nastoupil, N H Fowler, et al.
Brain and Cognition|May 1, 1990
Predicting cognitive recovery from closed head-injury in children and adolescentsC A Tompkins, A L Holland, G Ratcliff, et al.
Leukemia & Lymphoma|January 14, 2016
The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab eraR J Cassidy, N Jegadeesh, J Switchenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2015
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†C Casulo, B Day, K L Dawson, et al.
ESMO Open|April 1, 2026
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD studyJ Trotman, K Bouabdallah, F Bijou, et al.
Pageof 4